Laytonsville, MD, United States of America

Michael Scott Kinch

This inventor holds 19 USPTO granted patents and 17 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Purdue Research Foundation, University of Pittsburgh, Functional Genetics, Inc.. Active years: 2005-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Scott Kinch. Retrieved from https://idiyas.com/inventor/michael-scott-kinch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 17)

% Patents Active = 42.1

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 104(Granted Patents)

Location History:

Lafayette, IN (US) (2007)
Laytonville, MD (US) (2010)
Laytonsville, MD (US) (2005 - 2023)

Company Filing History:

7 out of 2,786

Purdue Research Foundation

patents

5 out of 1,963

University of Pittsburgh

patents

3 out of 11

Functional Genetics, Inc.

Smithkline Beecham Corporation

patents

6. 1 out of 4,517

Eli Lilly and Company

patents

7. 2 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2005-2023

Loading Chart...

Areas of Expertise:

EphA2 Agonists

Anti-TSG101 Antibodies

HIV Inhibition

Cancer Treatment

Therapeutic Targeting

Metastatic Disease

EphA4 Antibodies

Protein Tyrosine Phosphatase

Viral Infection

Monoclonal Antibodies

Epitope Agonists

Diagnostic Target

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11787846 - EphA2 T-cell epitope agonists and uses therefore (2023-10-17),

2. 10781240 - EPHA2 t-cell epitope agonists and uses therefore (2020-09-22),

3. 10131699 - EphA2 T-cell epitope agonists and uses therefore (2018-11-20),

4. 9359402 - EphA2 T-cell epitope agonists and uses therefore (2016-06-07),

5. 8796423 - Anti-TSG101 antibodies and their uses for treatment of viral infections (2014-08-05),

6. 8591887 - EPHA2 as a therapeutic target for cancer (2013-11-26),

7. 8535684 - Methods of inhibiting HIV infectivity (2013-09-17),

8. 8207209 - Methods of inhibiting viral infection (2012-06-26),

9. 8114407 - EphA2 T-cell epitopes and uses therefor (2012-02-14),

10. 7981410 - Therapeutic targeting of escort proteins (2011-07-19),

11. 7964708 - Anti-TSG101 antibodies and their uses for treatment of viral infections (2011-06-21),

12. 7776327 - EphA2 as a therapeutic target for cancer (2010-08-17),

13. 7662770 - Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target (2010-02-16),

14. 7604799 - EphA4 Antibodies (2009-10-20),

15. 7402298 - EphA2 monoclonal antibodies and methods of making and using same (2008-07-22),

Title: The Innovations of Michael Scott Kinch

Introduction

Michael Scott Kinch, hailing from Laytonsville, MD, is a distinguished inventor with an impressive portfolio of 19 patents. His contributions primarily focus on the innovative realms of immunology and cancer treatment. Kinch's work is notable for its potential impact on therapies for cancers that overexpress EphA2, particularly renal cell carcinoma.

Latest Patents

Among his latest advancements, Kinch has developed patents related to EphA2 T-cell epitope agonists. These patents detail the specific peptides derived from human EphA2 protein, which contain one or more T-cell epitopes and conservative derivatives. The innovative EphA2 T-cell epitopes hold substantial clinical utility as they can be utilized in assays, such as ELISPOT assays, to assess and quantify a patient's immune response to EphA2. Additionally, these epitopes play a crucial role in modulating a patient's immune reactivity to EphA2, paving the way for novel treatments for cancers like renal cell carcinoma (RCC). Furthermore, Kinch's research includes methods to vaccinate patients against EphA2 using both in vivo and ex vivo approaches.

Career Highlights

Michael Scott Kinch has collaborated with prominent institutions, including the Purdue Research Foundation and the University of Pittsburgh - of the Commonwealth System of Higher Education. His work within these esteemed organizations has significantly contributed to the advancement of cancer immunotherapy.

Collaborations

Kinch has worked alongside notable colleagues, including Walter J. Storkus and Nicole D. Zantek. Their combined expertise has advanced the research and development of innovative therapies targeting EphA2, demonstrating the power of collaboration in scientific advancements.

Conclusion

Through his inventions and patents, Michael Scott Kinch is making strides in the fight against cancer. His work on EphA2 T-cell epitopes represents a promising frontier in immunotherapy, showcasing the potential for innovative treatments that can improve patient outcomes. With his numerous patents and collaborative efforts, Kinch continues to be a pivotal figure in the landscape of medical innovation.

Profile summary based on public USPTO records.